THE MEASUREMENT PARTNER — BETWEEN FIERCELY INDEPENDENT NETWORKS AND THE PLANS THAT PAY FOR THEM
Barbara McAneny, MD has set out to build something patient and large: a nationwide network of independent oncologists — and then, on the same path, nationwide networks of the other independent specialists the consolidators have squeezed. A health plan and an independent network have rarely had reason to trust one another. Forward Health Group helps support that work — aligning them on a single incentive, so each is rewarded when outcomes improve, and showing, on the plan’s own data, that the savings are real. None of this is a simple path — but it is a navigable one, taken smartly and together.
THE THESIS, IN ONE LINE
Barbara is building the network. Forward Health Group helps support it — aligning the plan and the network on one incentive, and showing, on the plan’s own data, what the network saves and where it should grow.
Barbara and ONCare are never the source of Forward Health Group’s reimbursement. That reimbursement is always transparent, and it comes from the health plans. It does not draw on the ONCare funding pool, and it places no tax on the physicians in Barbara’s network. Rather, it is the funding that helps the network grow — and that, in turn, increases the revenue sharing returning to ONCare.
Built on Solventum’s Clinical Risk Groups (CRGs) — the claims grouping the plans already license — so the bridge extends to each new specialty, each new practice, and each new plan.
HCSC sets the model the other Blues follow. The executives who champion it are the ones who led — and their standing is enriched by being first, not last.
It begins as a contained pilot — on the plan’s own claims, in the plan’s own environment, with no downside risk — proving the savings before anything scales.
Keeping independent oncology alive means better cancer access at lower cost — an advantage HCSC holds over United and Humana, who are squeezing the very same practices.
And the economics hold: the plan may pay the physician side a little more — correcting today’s underpayment — and recovers it many times over from the hospital systems, once the true cost of optimal care is known.
What this brings into view: the same cardiac echo, ordered in-network, can cost four times as much in one place as another — and today that difference goes unseen. Seen in one view, the waste can be removed, and what is saved becomes the shared source that funds both the plan’s growth and the network’s.
Zoadigm plays an important role on this side — its platform turns the plan’s onerous requirements into background workflow at the practice, so clinicians spend their time on patients, not prior authorizations and paperwork.
The proven independent oncology practice — the COME HOME heritage that keeps patients out of the hospital and the ED.
Barbara’s separate New Mexico vehicle — a first-of-its-kind multi-specialty CIN, alongside the ONCare oncology alliance, not part of it. Not built on a hospital or on primary care. It controls specialty access in its market, so the plans that contract get priority — shifting the balance of power. One contract; CKD the start-small demonstration.
A nationwide network of independent oncologists — then, on the same playbook, nationwide networks of other disaffected independent specialists, settled on infrastructure the plans already hold.
The path out runs through HCSC’s own footprint — New Mexico first, then Illinois, Texas, and Oklahoma — to the ONCare practices within it, and outward to the broader Blue Cross Blue Shield Federation.
Holds the plan and the network to one shared measure — value created by removing waste, not by adding volume — so neither must take the other on trust.
Shows, on the plan’s own claims, where patients leak to higher-cost settings and where the network has gaps — so the plan sees where helping Barbara expand returns most.
Measures the PMPM the model has already taken out — independently, on a calculation neither side can tilt — and projects what a larger network would save, so the network keeps its share and control never shifts to the plan.
FHG measures the outcome; Zoadigm operationalizes the care — the workflow and coordination layer that keeps practices focused on care delivery, not the plan’s administrative machinery. Complementary lanes, one aligned model.
THE THESIS, IN ONE LINE
Barbara is building the network. Forward Health Group helps support it — aligning the plan and the network on one incentive, and showing, on the plan’s own data, what the network saves and where it should grow.
CRGs, IN PLAIN TERMS
Clinical Risk Groups are Solventum’s method for sorting a covered population into clinically coherent risk groups. Health plans already license and run them — so settling chronic-disease care on CRGs means switching on something the plan already has, not building something new. The work runs on the plan’s own claims, in the plan’s own environment; the data stays the plan’s.
NEXT STEP
A short conversation — Barbara and Michael — to align on FHG’s role and to accelerate and advance Zoadigm’s growth and adoption, with HCSC / BCBS New Mexico as the national pioneer. Not a simple path — but one we navigate smartly, together.